IDO1 anticorps

N° du produit ABIN1169196

Cité dans 5 publications. Cet anticorps anti-IDO1 Polyclonal Lapin (ABIN1169196) détecte spécifiquement IDO1 dans WB, ELISA, FACS et ICC. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour IDO1 anticorps (ABIN1169196)

Antigène: IDO1 (Indoleamine 2,3-Dioxygenase 1 (IDO1))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp IDO1 est non-conjugé

Application: Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunocytochemistry (ICC)

Détail du produit anti-IDO1 anticorps

Fonction: anti-IDO (human), pAb

Specificité: Recognizes human IDO1. Detects a band of ~45 kDa by Western blot.

Attributs du produit: Polyclonal Antibody. Recognizes human IDO. Detects a band of ~45 kDa by Western blot. Source: Rabbit. Applications: ELISA, FACS, ICC, WB. Liquid. 0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives. IDO catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway. Proinflammatory mediators, such as endotoxin and IFN-gamma induce the expression of IDO in several tissues. IDO-dependent suppression of T-cell responses might function as natural immunoregulatory mechanism. Physiological IDO activity has been implicated in T-cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.

Stérilité: 0.2 μm filtered

Immunogène: Recombinant human IDO1.

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 0.2μm-filtered solution in PBS, pH 7.4.

Agent conservateur: Without preservative

Conseil sur la manipulation: After opening, prepare aliquots and store at -20 °C.Avoid freeze/thaw cycles.

Stock: 4 °C,-20 °C

Stockage commentaire:

+4°C

-20°C

Stable for at least 6 months after receipt when stored at -20°C.

Date de péremption: 6 months

Références pour anticorps anti-IDO1 (ABIN1169196)

Pietra, Manzini, Rivara, Vitale, Cantoni, Petretto, Balsamo, Conte, Benelli, Minghelli, Solari, Gualco, Queirolo, Moretta, Mingari: "Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity." dans: Cancer research, Vol. 72, Issue 6, pp. 1407-15, (2012) (PubMed).

Opitz, Litzenburger, Opitz, Sahm, Ochs, Lutz, Wick, Platten: "The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells." dans: PLoS ONE, Vol. 6, Issue 5, pp. e19823, (2011) (PubMed).

Curti, Trabanelli, Onofri, Aluigi, Salvestrini, Ocadlikova, Evangelisti, Rutella, De Cristofaro, Ottaviani, Baccarani, Lemoli: "Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells." dans: Haematologica, Vol. 95, Issue 12, pp. 2022-30, (2010) (PubMed).

Maby-El Hajjami, Amé-Thomas, Pangault, Tribut, DeVos, Jean, Bescher, Monvoisin, Dulong, Lamy, Fest, Tarte: "Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase." dans: Cancer research, Vol. 69, Issue 7, pp. 3228-37, (2009) (PubMed).

Boasso, Herbeuval, Hardy, Anderson, Dolan, Fuchs, Shearer: "HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells." dans: Blood, Vol. 109, Issue 8, pp. 3351-9, (2007) (PubMed).

Détails sur IDO1

Antigène: IDO1 (Indoleamine 2,3-Dioxygenase 1 (IDO1))

Autre désignation: IDO

Sujet:

Alternate Names/Synonyms: Indoleamine 2,3-dioxygenase 1, IDO, INDO

Product Description: IDO1 is a heme enzyme that catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway, causing depletion of tryptophan which can lead to halted growth of microbes as well as T cells. IDO1 is an immune checkpoint protein, thought to play a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation and antioxidant activity. Cancer cells are able to evade the immune system is by hijacking the checkpoint proteins. Increased IDO1 protein levels drive growth arrest and apoptosis of the effector T cells, a group of immune cells that mediate the immune system's ability to destroy pathogens. By reducing the number of effector T cells, IDO1 overexpression prevents the immune system from effectively destroying cancer cells. IDO1 overexpression has been observed in a wide range of human cancers such as prostatic, colorectal, pancreatic, cervical, gastric, ovarian, head or lung cancer. Physiological IDO1 activity has been implicated in T cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.

UniProt: P14902

Pathways: Activated T Cell Proliferation